TScan Phase 1 TCR-T data: 6/6 patients achieve complete donor chimerism and MRD negativity; 0/4 controls

TScan Therapeutics, Inc.

All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.
One AML patient MRD-positive post-HCT converted to MRD-negative after TSC-101 treatment.
Control arm: one TP53-mutated MDS patient relapsed at ~6 months; two others had worsening chimerism requiring clinical intervention.
Dose escalation reached third and final level with no dose-limiting toxicities; recommended Phase 2 dose expected from this level.
Company hosting virtual KOL event Dec 11 to discuss data; 10 clinical sites active with expansion cohorts planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.